Clinical Efficacy of Pretransplant Vaccination for Preventing Herpes Zoster After Living Donor Liver Transplantation in Recipients Aged 50 Years and Older

    loading  Checking for direct PDF access through Ovid

Abstract

Objectives

There have been no reports concerning the efficacy of pretransplant herpes zoster (HZ) vaccination following living donor liver transplantation (LDLT). From January 2013 to May 2016, 24 patients aged 50 years and older received vaccination of HZ prior to transplantation and underwent LDLT at a single institution.

Methods

We compared this to the one-year HZ incidence of unvaccinated recipients (N = 180) who underwent LDLT in the same time frame.

Results

For general characteristics, the MELD scores (p < 0.001) and CTP grades (p = 0.007) of the vaccinated group were significantly lower than those of unvaccinated group. In Kaplan-Meier analysis, the one- year HZ incidence rates of the vaccinated and unvaccinated groups were two (8.7%) and 16 (9.9%) cases, respectively (p = 0.883). In the subgroup aged 50 through 59 years, two vaccinated recipients had HZ after LDLT. However, in the subgroup aged 60 years and older, no vaccinated recipients had HZ after LDLT. Multivariate analysis showed the independent risk factor for HZ after LDLT was use of mycophenolate mofetil (MMF; hazard ratio [HR] = 3.00; p = 0.041).

Conclusion

the efficacy of pretransplant vaccination for preventing HZ was not apparent in our study. A large prospective study is needed to determine the indications for pretransplant HZ vaccination according to age group and to evaluate the efficacy of HZ vaccination after LDLT.

Related Topics

    loading  Loading Related Articles